Investment Thesis
Jasper Therapeutics is a pre-revenue biotech company with -$246K revenue, -$83.9M operating losses, and a -$77.2M operating cash burn rate, providing only ~4.5 months of cash runway at current burn rates. The weak equity position ($4.2M vs $31.6M liabilities) and deteriorating financial trajectory indicate unsustainable fundamentals with significant default risk.
Strengths
- Strong liquidity position with 2.62x current ratio and quick ratio
- Substantial cash reserve of $28.7M providing near-term runway
- No long-term debt burden (0.00x debt/equity ratio)
Risks
- Negative and declining revenue (-113.9% YoY) indicating failed commercial traction
- Massive operating losses (-$83.9M) with unsustainable cash burn of -$77.2M per period
- Critically weak stockholders' equity ($4.2M) relative to liabilities ($31.6M) creates insolvency risk
- Minimal insider activity (1 Form 4 filing in 90 days) suggests low confidence from company leadership
- Limited cash runway of approximately 4.5 months based on current burn rate
Key Metrics to Watch
- Monthly operating cash burn rate and timeline to profitability or additional financing
- Revenue inflection point and path to positive revenue growth
- Stockholders' equity trend and solvency metrics
- Capital raise announcements or debt issuance to extend runway
Financial Metrics
Revenue
-246.0K
Net Income
-75.8M
EPS (Diluted)
$-3.95
Free Cash Flow
-77.2M
Total Assets
35.8M
Cash
28.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
34,098.8%
Net Margin
30,813.4%
ROE
-1,826.1%
ROA
-211.9%
FCF Margin
31,366.3%
Balance Sheet & Liquidity
Current Ratio
2.62x
Quick Ratio
2.62x
Debt/Equity
0.00x
Debt/Assets
88.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T23:00:21.831166 |
Data as of: 2025-12-31 |
Powered by Claude AI